Evidence map›Paper›PMID 40295790›Full record

ArticleNpj viruses2024

Tracing household transmission of SARS-CoV-2 in New Zealand using genomics.

Lauren Jelley, Nayyereh Aminisani, Meaghan O'Neill, Tineke Jennings, Jordan Douglas, Srushti Utekar, Helen Johnston, David Welch, James Hadfield, SHIVERS Investigation Team and 7 more

Abstract read
In one paragraph

Article in Npj viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Post-Covid-19 Symptoms in Children: A Cross-Sectional Survey.Journal of paediatrics and child health · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lauren JelleyInstitute of Environmental Science and Research, Wellington, New Zealand.
Nayyereh AminisaniInstitute of Environmental Science and Research, Wellington, New Zealand.
Meaghan O'NeillInstitute of Environmental Science and Research, Wellington, New Zealand.
Tineke JenningsRegional Public Health, Te Whatu Ora-Health New Zealand Capital, Coast and Hutt Valley, Wellington, New Zealand.
Jordan DouglasCentre for Computational Evolution, University of Auckland, Auckland, New Zealand.
Srushti UtekarInstitute of Environmental Science and Research, Wellington, New Zealand.
Helen JohnstonInstitute of Environmental Science and Research, Wellington, New Zealand.
David WelchCentre for Computational Evolution, University of Auckland, Auckland, New Zealand.
James HadfieldFred Hutchinson Cancer Research Centre, Seattle, WA, USA.
SHIVERS Investigation Team
Joep de LigtInstitute of Environmental Science and Research, Wellington, New Zealand.
David WinterInstitute of Environmental Science and Research, Wellington, New Zealand.
Nigel FrenchTāwharau Ora/School of Veterinary Science, Massey University, Palmerston North, New Zealand.
Paul G ThomasDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
Richard J WebbyDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
Sue HuangInstitute of Environmental Science and Research, Wellington, New Zealand.
Jemma L GeogheganInstitute of Environmental Science and Research, Wellington, New Zealand. jemma.geoghegan@otago.ac.nz.

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4M
Household Respiratory Virus SARS-CoV-2 Transmission and Immunity Sub-Study (HRTS)U01AI144616 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GORDON, AUBREE L, THOMAS, PAUL G. · 2019 to 2025
$43.7M
New Zealand Health Research Council Grant 22/138NIAID NIH HHS 75N93021C00016NIAID NIH HHS U01 AI144616US-NIAID U01 AI 144616
6 · The paper itself

Abstract

By early 2022, the highly transmissible Omicron variant of SARS-CoV-2 had spread across most of the world. For the first time since the pandemic began, New Zealand was experiencing high levels of community transmission of SARS-CoV-2. We enroled a cohort of households to better understand differences in transmission dynamics among subvariants of Omicron. We enroled 71 households, comprising 289 participants, and aimed to use viral genomes to gain a clearer understanding of variant-specific differences in epidemiological parameters affecting transmission dynamics. Approximately 80% of the households enroled experienced transmission of BA.2, while most of the remaining households had infections with BA.1 or BA.5. Using a logistic regression generalised linear mixed model, we found no difference in household secondary infection rate between Omicron subvariants BA.1, BA.2 and BA.5. Of the households recruited, the vast majority (92%) experienced a single chain of transmission with one inferred introduction. Further, we found that in 48% of the households studied, all household participants became infected following an index case. Most household participants tested positive within a week following an introduction, supporting the seven-day isolation requirement for household contacts that was in place in New Zealand at the time. By integrating genomic and epidemiological data, we show that viral transmission dynamics can be investigated with a higher level of granularity than with epidemiological data alone. Overall, households are a high risk setting for viral transmission in New Zealand.

Identifiers

PMID40295790
PMCPMC11721343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.